| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/15-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | ALK7; ACVRLK7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ACVR1C |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ACVR1C抗体的3篇示例参考文献(虚构示例，仅供格式参考)：
1. **"Development of a monoclonal antibody targeting ACVR1C for pancreatic cancer therapy"**
*Authors: Smith J, et al. (2020)*
*摘要*：本研究报道了一种新型抗ACVR1C单克隆抗体的开发，通过体外实验验证其可特异性抑制ACVR1C介导的SMAD2/3磷酸化，并在胰腺癌小鼠模型中显著降低肿瘤生长和转移。
2. **"ACVR1C antibody-based detection of activin signaling in metabolic disorders"**
*Authors: Lee S, et al. (2018)*
*摘要*：利用高灵敏度的ACVR1C多克隆抗体，作者揭示了ACVR1C在肥胖相关脂肪组织中的异常激活，提示其作为代谢综合征生物标志物的潜力。
3. **"Characterization of ACVR1C-neutralizing antibodies in colorectal cancer models"**
*Authors: Zhang Y, et al. (2021)*
*摘要*：通过筛选人源化ACVR1C抗体库，鉴定出具有阻断配体结合能力的抗体，证明其可逆转结直肠癌细胞的上皮-间质转化(EMT)过程，抑制体内肿瘤侵袭。
4. **"ACVR1C-specific antibodies reveal distinct expression patterns in normal vs. fibrotic liver tissues"**
*Authors: Garcia R, et al. (2019)*
*摘要*：开发了一种免疫组化用ACVR1C抗体，系统分析了其在肝纤维化中的动态表达，发现ACVR1C与TGF-β协同驱动肝星状细胞活化，为抗纤维化治疗提供新靶点。
(注：上述文献为模拟内容，实际引用需查询PubMed等数据库获取真实研究。)
The ACVR1C antibody targets activin receptor-like kinase 7 (ALK7), a type I transmembrane serine/threonine kinase receptor in the TGF-β superfamily. ACVR1C/ALK7 binds activins, nodal, and growth differentiation factors (GDFs), mediating SMAD-dependent signaling pathways critical for cellular processes like differentiation, apoptosis, and metabolism. It is expressed in tissues including adipose, pancreas, and the nervous system, and has been implicated in metabolic regulation, cancer, and fibrosis.
ACVR1C antibodies are valuable tools for research, enabling detection of receptor expression, localization, and activation in disease models. In cancer, ACVR1C overexpression or mutation may drive tumor progression, making it a potential therapeutic target. Antibodies blocking ACVR1C activity are explored for inhibiting oncogenic signaling. Conversely, in metabolic disorders, modulating ACVR1C signaling could influence insulin sensitivity or lipolysis.
Commercial ACVR1C antibodies are typically monoclonal or polyclonal, validated for applications like Western blot, immunohistochemistry, or flow cytometry. Challenges include ensuring specificity due to homology with other TGF-β receptors. Recent studies also investigate ACVR1C's role in fibrosis and immune regulation, expanding its therapeutic relevance. Developing therapeutic antibodies or small-molecule inhibitors against ACVR1C remains an active area, with ongoing preclinical studies assessing efficacy and safety in related pathologies.
×
